Upstream Bio, Inc.

The UK’s respiratory heavyweights are locking horns again with AstraZeneca and GSK trumpeting positive data on their respective treatments for chronic rhinosinusitis with nasal polyps (CRSwNP). First

Biotech IPOs staged a moderate recovery in 2024 but a muted end to the year showed how fragile the market remains for companies looking to launch. Full year data shows 26 companies debuted on US excha

AstraZeneca and Amgen are holding most of their cards close to the vest, but Phase III data they reported on 8 November may be adequate to file their anti-TSLP agent Tezspire (tezepelumab) for a secon

Stock market listings were back on the upswing last quarter, with the eight biotechs floating on Western exchanges raising a total of $1.1bn. In fact, there seems to have been a bit of a rush: three c